Imunon, Inc.
Imunon, Inc. (IMNN): 3 pipeline candidates · 3 upcoming catalysts · ~4 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.0 months
D/E 1.39 · 28% dilution
Lead: Phase 3
3 candidates
3 upcoming, next in ~2327d
N/A
A transparent, data-derived signal for Imunon, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.2M
Cash
$4.8M
Quarterly Burn
$4.0M
Runway
4.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$1.5M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 348,330 | $1.0M |
| vanguard capital management llc | 96,112 | $283K |
| geode capital management, llc | 33,211 | $98K |
| vanguard fiduciary trust co | 13,269 | $39K |
| blackrock, inc. | 4,464 | $13K |
| wells fargo & company/mn | 3,342 | $10K |
| morgan stanley | 3,035 | $9K |
| sbi securities co., ltd. | 1,027 | $3K |
| ubs group ag | 575 | $2K |
| hrt financial lp | 12,055 | $35 |
Showing top 10 of 17 institutional holders of Imunon, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Imunon, Inc.'s pipeline?
Imunon, Inc. (IMNN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Imunon, Inc.'s lead drug candidate?
Imunon, Inc.'s most advanced tracked candidate is imnn-001 (Phase 3) for Epithelial Ovarian Cancer; Ovarian Cancer.
What is Imunon, Inc.'s next catalyst?
Imunon, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati" — expected October 31, 2032.
What is Imunon, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Imunon, Inc. has approximately 4.0 months of cash runway.
What is Imunon, Inc.'s market capitalization?
Imunon, Inc.'s market capitalization is approximately $8.2M.
Get the full picture on Imunon, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.